Conference abstract · 24 Apr 2017
Conference abstractPublished 21 Oct 2013
Regulatory environment and process in Turkey
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Turkey is a developing and emerging country which ranks as the 16th largest pharmaceutical manufacturer worldwide and the 6th largest in Europe and expected to rise in the upcoming years. The government released its action plan in 2012 for the pharmaceutical industry key highlights were to increase R&D expenditures, export activities and investment possibilities. The healthcare system in Turkey has gone through a serious reform process with the 2003-2013 health transformation program. Many regulations changed, one of the most significant changes was implemented in Aug 2009; it was the obligation of GMP inspection of import products by Turkish inspectors. Due to unbalanced ratio of import products vs. local products and global budget the government implemented such a requirement before new submissions.The government supports local manufacturing and therefore since 2009 the number of import registrations decreased significantly (in 2012, 74% local registrations 26% import registrations.) Turkey?s pharmaceutical regulations are generally in line with EU however there are some national deviations which may be a challenge for global companies. CTD format is applicable for the submission and the product is evaluated under several commissions once it is submitted such as advisory, technology, pharmacology, analysis of samples. Price can be submitted in parallel during registration phase or right after. In theory, registration process ends in 210 days however this is not the general case in practice. The recent examples show that it takes 15 months to three years. Despite many challenges such as regulation implementation without a reasonable transition period and price cuts, there are still opportunities as its one of the fastest growing markets with its 75 million populations.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 21 Oct 2013
Regulatory requirements of drug products for human use in EU and Turkey
Article · 29 Mar 2024
Evolving Role of Regulatory Agencies in a Globalized Pharmacovigilance Environment
Conference abstract · 29 Sep 2016
Pharmaceutical regulatory environment with perspective on the International GMPs
Conference abstract · 29 Sep 2016
Pharmaceutical Regulatory environment with perspective on the International GMP's
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Cigdem Yilmaz”

